Skip Navigation



Carcinogenesis Advance Access published online on May 4, 2006
Carcinogenesis, doi:10.1093/carcin/bgl047
This Article
Right arrow Advance Access manuscript (PDF) Freely available
Right arrow All Versions of this Article:
27/10/2028    most recent
bgl047v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Li, G.
Right arrow Articles by Wei, Q.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, G.
Right arrow Articles by Wei, Q.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org
Received December 9, 2005
Revised March 2, 2006
Accepted March 31, 2006

MOLECULAR EPIDEMIOLOGY AND CANCER PREVENTION

MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis

Guojun Li 1, Xiaodong Zhai 1, Zhengdong Zhang 1, Robert M. Chamberlain 1, Margaret R. Spitz 1, and Qingyi Wei 1 *

1 Department of Epidemiology, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA

* To whom correspondence should be addressed.
Qingyi Wei, E-mail: qwei{at}mdanderson.org


  Abstract

The MDM2 protein negatively regulates p53 level in modulating DNA repair, cell-cycle control, cell growth and apoptosis. Polymorphisms in the promoter region of the MDM2 gene have been shown to alter protein expression and may thus play a role in carcinogenesis. To test our hypothesis that the MDM2 promoter polymorphisms are associated with risk of lung cancer, we conducted a hospital-based, case-control study of 1026 non-Hispanic white patients newly diagnosed with lung cancer and 1145 cancer-free controls who were frequency-matched by age (±5 years), sex, ethnicity, and smoking status. We genotyped for the MDM2 promoter G2580T (also called SNP309) and G2164A polymorphisms that have a minor allele frequency greater than 0.05. The distributions of the MDM2-2580G variant allele and genotypes were significantly less common among the cases than among the controls (P = 0.038 and 0.045, respectively), but this was not evident for MDM2G2164A (P = 0.865 and 0.614, respectively). Compared with the MDM2-2580TT genotype, the MDM2-2580G variant genotypes were associated with a decreased risk of lung cancer (odds ratio = 0.81 and 95% confidence interval = 0.67-0.98 for MDM2GT, 0.83 [0.63-1.08] for MDM2GG, and 0.81 [0.68-0.97] for the combined GT/GG genotype), a finding that seems to contradict previous reports. However, no significant association was observed between the MDM2G2164A variant genotypes and lung cancer risk. Our results suggest that the MDM22580G allele may be a marker of genetic susceptibility to lung cancer in non-Hispanic white population.

Keywords: MDM2; genetic susceptibility; polymorphism; lung cancer; molecular epidemiology.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cancer Res.Home page
C. Canova, M. Hashibe, L. Simonato, M. Nelis, A. Metspalu, P. Lagiou, D. Trichopoulos, W. Ahrens, I. Pigeot, F. Merletti, et al.
Genetic Associations of 115 Polymorphisms with Cancers of the Upper Aerodigestive Tract across 10 European Countries: The ARCAGE Project
Cancer Res., April 1, 2009; 69(7): 2956 - 2965.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
Y. J. Yoon, H. Y. Chang, S. H. Ahn, J. K. Kim, Y. K. Park, D. R. Kang, J. Y. Park, S. M. Myoung, D. Y. Kim, C. Y. Chon, et al.
MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection
Carcinogenesis, June 1, 2008; 29(6): 1192 - 1196.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
Z. Hu, G. Jin, L. Wang, F. Chen, X. Wang, and H. Shen
MDM2 Promoter Polymorphism SNP309 Contributes to Tumor Susceptibility: Evidence from 21 Case-Control Studies
Cancer Epidemiol. Biomarkers Prev., December 1, 2007; 16(12): 2717 - 2723.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
S. Wilkening, J. L. Bermejo, and K. Hemminki
MDM2 SNP309 and cancer risk: a combined analysis
Carcinogenesis, November 1, 2007; 28(11): 2262 - 2267.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. S. Heist, W. Zhou, L. R. Chirieac, T. Cogan-Drew, G. Liu, L. Su, D. Neuberg, T. J. Lynch, J. C. Wain, and D. C. Christiani
MDM2 Polymorphism, Survival, and Histology in Early-Stage Non-Small-Cell Lung Cancer
J. Clin. Oncol., June 1, 2007; 25(16): 2243 - 2247.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Sanchez-Carbayo, N. D. Socci, T. Kirchoff, N. Erill, K. Offit, B. H. Bochner, and C. Cordon-Cardo
A Polymorphism in HDM2 (SNP309) Associates with Early Onset in Superficial Tumors, TP53 Mutations, and Poor Outcome in Invasive Bladder Cancer
Clin. Cancer Res., June 1, 2007; 13(11): 3215 - 3220.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Zhou, Y. Zhai, Y. Cui, X. Zhang, X. Dong, H. Yang, Y. He, K. Yao, H. Zhang, L. Zhi, et al.
MDM2 Promoter SNP309 Is Associated with Risk of Occurrence and Advanced Lymph Node Metastasis of Nasopharyngeal Carcinoma in Chinese Population
Clin. Cancer Res., May 1, 2007; 13(9): 2627 - 2633.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.